A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.-Reference-Cited by-同舟云学术

A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:9044-9044
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Albertini Mark R.¹,Ranheim Erik²,Hank Jacquelyn A¹,Zuleger Cindy³,McFarland Thomas²,Collins Jennifer³,Clements Erin³,Weber Sharon M.²,Weigel Tracey⁴,Neuman Heather B.¹,Hartig Gregory K¹,Mahvi David⁵,Henry MaryBeth²,Gan Jacek¹,Yang Richard²,Kim KyungMann³,Gillies Stephen⁶,Sondel Paul M.¹

Affiliation:

1. University of Wisconsin, Madison, WI

2. University of Wisconsin, School of Medicine and Public Health, Madison, WI

3. University of Wisconsin Carbone Cancer Center, Madison, WI

4. Maine Medical Center, Portland, ME

5. Feinberg School of Medicine, Northwestern University, Chicago, IL

6. Provenance Biopharmaceuticals Corp., Carlisle, ME

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.9044

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trial watch: intratumoral immunotherapy;OncoImmunology;2021-01-01

2. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation;New Biotechnology;2019-09

3. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma;Cancer Immunology, Immunotherapy;2018-08-03